Attruby is specifically designed to deliver
near-complete TTR stabilization^1-3

Why Stabilize TTR?

• TTR, or prealbumin, is essential for everyday health and function^4,5

• ATTR-CM is a disease of TTR destabilization^6-8

How ATTR-CM Develops

The level of TTR stabilization can help make a difference^11,12

• Stabilizing the TTR tetramer has become an important therapeutic target for slowing
  ATTR-CM progression⁹

That's why Attruby
was designed to^1-3:

• Mimic the properties of the T119M TTR mutation—
  a protective, naturally occurring stabilizing variant of TTR

• Achieve >90% in vitro
  TTR stabilization

See >90% TTR Stabilization You Can Measure

1

2

3

Scroll Down

Watch >90%
Stabilization in Action

Low rates of discontinuations due to adverse drug reactions and convenient dosing with Attruby¹

See Dosing & Safety

AE=adverse event; ATTR-CM=transthyretin amyloid cardiomyopathy; GI=gastrointestinal; TTR=transthyretin.

References: 1. Attruby. Prescribing information. BridgeBio, Inc.; 2024. 2. Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. 2024;390(2):132-142. doi:10.1056/NEJMoa2305434 3. Hammarström P, Jiang X, Hurshman AR, Powers ET, Kelly JW. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA. 2002;99(Suppl 4):16427-16432. doi:10.1073/pnas.202495199 4. Liz MA, Coelho T, Bellotti V, Fernandez-Arias MI, Mallaina P, Obici L. A narrative review of the role of transthyretin in health and disease. Neurol Ther. 2020;9(2):395-402. doi:10.1007/s40120-020-00217-0 5. Vieira M, Saraiva MJ. Transthyretin: a multifaceted protein. Biomol Concepts. 2014;5(1):45-54. doi:10.1515/bmc-2013-0038 6. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872-2891. doi:10.1016/j.jacc.2019.04.003 7. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1): e7-e22. doi:10.1161/CIR.0000000000000792
8. Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail. 2019;7(8):709-716. doi:10.1016/j.jchf.2019.04.010 9. Morfino P, Aimo A, Vergaro G, et al. Transthyretin stabilizers and seeding inhibitors as therapies for amyloid transthyretin cardiomyopathy. Pharmaceutics. 2023;15(4):1129. doi:10.3390/pharmaceutics15041129 10. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451-2466. doi:10.1016/j.jacc.2015.09.075 11. Angueira A, Abramowitz SA, Levin MG. Unfolding the link between transthyretin stability and survival. JAMA Cardiol. Published online December 4, 2024. doi:10.1001/jamacardio.2024.4112 12. Christoffersen M, Greve AM, Hornstrup LS, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Transthyretin tetramer destabilization and increased mortality in the general population. JAMA Cardiol. Published online December 4, 2024. doi:10.1001/jamacardio.2024.4102 13. Hanson JLS, Arvanitis M, Koch CM, et al. Use of serum transthyretin as a prognostic indicator and predictor of outcome in cardiac amyloid disease associated with wild-type transthyretin. Circ Heart Fail. 2018;11(2): e004000. doi:10.1161/CIRCHEARTFAILURE.117.004000 14. Greve AM, Christoffersen M, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Association of low plasma transthyretin concentration with risk of heart failure in the general population. JAMA Cardiol. 2021;6(3):258-266. doi:10.1001/jamacardio.2020.5969
15. Data on file. BridgeBio, Inc.; 2024.

Current state of care in ATTR-CM is not enough

Within 2.5 years of initiation* on current treatments,

HOSPITALIZED

DIED

≥90% TTR stabilization could make all
the difference

*Data from a non-Attruby clinical study that treated a more severe patient population with a TTR stabilizer.

ATTR-CM=transthyretin amyloid cardiomyopathy; TTR=transthyretin.

How ATTR-CM
Develops

TTR is a key transport protein that binds to and transports vitamin A and thyroxine throughout the body, and it performs its function when it's present and stable.^4,5

In ATTR-CM, aging or genetic variants can cause TTR to destabilize and break apart into monomers, which misfold and accumulate as toxic amyloid fibrils throughout the body, including in the myocardium.^6-8

By preserving TTR structure and slowing toxic amyloid fibril formation, TTR stabilizers may help alter the natural course of the disease.^9,10

ATTR-CM=transthyretin amyloid cardiomyopathy; TTR=transthyretin.

Why Mimic the Proven Approach of T119m?

mimic the properties of the
T119M rescue mutation

ACHIEVE ≥90%
STABILIZATION

T119M is a protective, naturally occurring,
stabilizing variant of TTR

TTR=transthyretin.

Attruby demonstrated rapid and
sustained increase in serum TTR^1,2

Attruby delivered near-complete (>90%) in vitro
TTR stabilization in as early as 28 days^1,2

Key Secondary Endpoint: Change From Baseline in Serum TTR Level²*

Levels of serum TTR, also
known as prealbumin, are a
measure of stabilized TTR¹³

Testing can give you and your
patients the confidence of
knowing if Attruby is working

Lower TTR levels have been associated with worsening outcomes^13,14†

^*Per standard protocol, any missing values were imputed as placebo values.¹⁵

^†Based on a retrospective analysis of multivariate predictors of shorter overall survival in 116 patients with biopsy-proven ATTRwt.¹³

ATTRwt=wild-type transthyretin amyloidosis; TTR=transthyretin.